Luigi Meneghini, MD, MBA is Professor of Internal Medicine at the University of Texas Southwestern Medical Center, Division of Endocrinology, in Dallas, Texas, and Executive Director of the Parkland Health and Hospital System’s Global Diabetes Program, where he is charged with implementing a system-wide program to organize, integrate and optimize diabetes management among primary, specialty and acute care settings, leveraging IT and population health expertise, community resources and human capital to reduce chronic disease burden. Dr. Meneghini was born in Italy, raised in Liberia and naturalized in the US.
Robert S. Busch, MD, FACE
Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY
Robert Busch, M.D., is the Director of Clinical Research at Albany Med Faculty Practice; Community Endocrine Group. He went to Medical School at the University of Pennsylvania, and did his internship, residency and served as Chief Medical resident at North Shore University Hospital in Manhasset, N.Y. He is a practicing endocrinologist who enjoys teaching medical students, nurse practitioners, physician assistants and pharmacists for over 30 yrs. He has been the principal investigator for over 40 clinical trials of new therapies for diabetes and hyperlipidemia.
Intensive therapy for tight glycemic control improves long-term outcomes in patients with T2DM. However, diabetes care is generally suboptimal, and up to two-thirds of people with T2DM do not achieve glycemic targets. T2DM patients are at increased risk for microvascular and macrovascular complications, depending upon the duration of diabetes and degree of hyperglycemia. The SGLT2 inhibitors are newer options for T2DM management that, unlike other antidiabetic agents, do not target insulin deficiency and resistance in T2DM, and therefore offer a different approach for managing this condition. Given their mechanism of action, the SGLT2 inhibitors can facilitate glycemic control while avoiding hypoglycemia, and promoting weight loss. They also exert beneficial effects on multiple cardiovascular and renal risk parameters, as demonstrated in recent trials, and may confer cardiovascular and renal protection. When used in combination therapy with other anti-diabetic agents for T2DM, the SGLT2 inhibitors can exert additive/synergistic effects.
This activity utilizes segments of a presentation by the faculty recorded at one of the Emerging Challenges in Primary Care symposia, to reinforce teaching points made during this program. Participants can expect to learn how to effectively integrate the SLGT2 class of medications into practice and the emerging data surrounding renal and macrovascular effects of diabetes treatments.
Gregg Sherman, MD
National Association for Continuing Education
Harvey C. Parker, Ph.D., CCMEP National Association for Continuing Education Plantation, FL
Joshua Kilbridge, President Kilbridge Associates San Francisco, CA
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk, and Shire. Dr. Busch also serves as a researcher for Astra Zeneca, Novo Nordisk, Janssen, and Amgen.
Luigi Meneghini, MD, MBA serves as a consultant and advisory board member for Novo Nordisk and Sanofi Aventis.
Gregg Sherman, MD has no real or apparent conflicts of interest to report.
Harvey Parker, PhD has no real or apparent conflicts of interest to report.
Joshua Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
For CME questions, please contact: NACE at firstname.lastname@example.org
Contact this CME provider for privacy and confidentiality policy statement information at:
CREDIT DESIGNATION STATEMENT:
The National Association for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 hr contact hours of continuing education (which includes .50 hours of pharmacology)
TO OBTAIN CME CREDITS:
Read the learning objectives and faculty disclosures.
Participate in the activity.
Complete the post-test and activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit.
Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
You must score 60% or higher on the post-test to receive credit for this activity.
All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
This activity is sponsored by National Association for Continuing Education.
This activity is supported by educational funding provided by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
If you have any questions regarding this activity, send an email to email@example.com.
Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above.